Regulus Therapeutics Income Statement

Financials in millions JPY. Fiscal year is March - February.

Millions JPY. Fiscal year is Mar - Feb.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2021
Period Ending	May '25 May 31, 2025	Feb '25 Feb 28, 2025	Feb '24 Feb 29, 2024	Feb '21 Feb 28, 2021
Revenue	3,448	3,432	2,948	5,410
Revenue Growth (YoY)	-	16.40%	-45.51%	-
Cost of Revenue	2,281	2,333	1,949	4,924
Gross Profit	1,167	1,099	999.13	486.24
Selling, General & Admin	1,025	977.49	826.36	-
Other Operating Expenses	-	-	-	482.33
Operating Expenses	1,025	977.49	826.36	492.61
Operating Income	142.04	121.62	172.78	-6.37
Interest Expense	-10.2	-10.14	-10.74	-6.06
Other Non Operating Income (Expenses)	60.92	20.18	4.71	1.97
Pretax Income	192.76	131.66	166.75	-10.46
Income Tax Expense	67.71	45.28	52.39	-0.63
Net Income to Company	-	86.37	114.36	-
Net Income	125.06	86.37	114.36	-9.83
Net Income to Common	125.06	86.37	114.36	-9.83
Net Income Growth	-	-24.47%	-	-
Shares Outstanding (Basic)	2	2	2	-
Shares Outstanding (Diluted)	3	3	2	-
Shares Change (YoY)	-	9.13%	-	-
EPS (Basic)	54.36	37.54	55.11	-
EPS (Diluted)	49.04	33.87	48.94	-
EPS Growth	-	-30.79%	-	-
Free Cash Flow	-	135.94	323.2	-
Free Cash Flow Per Share	-	53.31	138.32	-
Dividend Per Share	6.500	6.500	6.000	-
Dividend Growth	-	8.33%	-	-
Gross Margin	33.85%	32.02%	33.89%	8.99%
Operating Margin	4.12%	3.54%	5.86%	-0.12%
Profit Margin	3.63%	2.52%	3.88%	-0.18%
Free Cash Flow Margin	-	3.96%	10.96%	-
EBITDA	-	140.42	183.74	3.91
EBITDA Margin	-	4.09%	6.23%	0.07%
D&A For EBITDA	-	18.8	10.96	-
EBIT	142.04	121.62	172.78	-6.37
EBIT Margin	4.12%	3.54%	5.86%	-0.12%
Effective Tax Rate	35.12%	34.39%	31.42%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.